title: The role and clinical significance of DNA damage response and repair pathways in primary brain tumors.
abstract: Primary brain tumors, in particular, glioblastoma multiforme (GBM), continue to have dismal survivability despite advances in treating other neoplasms. The goal of new anti-glioma therapy development is to increase their therapeutic ratios by enhancing tumor control and/or decreasing the severity and incidence of side effects. Because radiotherapy and most chemotherapy agents rely on DNA damage, the cell's DNA damage repair and response (DRR) pathways may hold the key to new therapeutic strategies. DNA double-strand breaks (DSBs) generated by ionizing radiation and chemotherapeutic agents are the most lethal form of damage, and are repaired via either homologous recombination (HR) or non-homologous end-joining (NHEJ) pathways. Understanding and exploitation of the differences in the use of these repair pathways between tumor and normal brain cells will allow for an increase in tumor cell killing and decreased normal tissue damage. A literature review and discussion on new strategies which can improve the anti-glioma therapeutic ratio by differentially targeting HR and NHEJ function in tumor and normal neuronal tissues is the focus of this article.
authors: Department of Radiation Oncology, The Ohio State University College of Medicine, 072A Starling Loving Hall, 300 W, 10th Avenue, Columbus, OH 43210, USA. fen.xia@osumc.edu.
authors: Wil L
authors: WL
authors: Santivasi
authors: Fen
authors: F
authors: Xia
references: DNA Repair (Amst). 2008 Oct 1;7(10):1765-71
references: 18675941
references: Oncogene. 2003 Sep 1;22(37):5784-91
references: 12947386
references: Int J Cancer. 2009 Jun 15;124(12):2948-53
references: 19330829
references: J Cell Physiol. 2006 Aug;208(2):267-73
references: 16523492
references: Cancer Res. 2010 Aug 1;70(15):6258-67
references: 20631074
references: Nature. 2005 Apr 14;434(7035):913-7
references: 15829966
references: Oncogene. 1999 May 20;18(20):3114-26
references: 10340383
references: Br J Cancer. 2008 Feb 12;98(3):523-8
references: 18231106
references: Mol Cell. 2002 Aug;10(2):387-95
references: 12191483
references: Cancer Res. 2008 Nov 15;68(22):9141-6
references: 19010885
references: Cancer Res. 2004 Aug 15;64(16):5560-3
references: 15313891
references: Cancer Sci. 2008 Feb;99(2):187-94
references: 17953711
references: Nat Rev Mol Cell Biol. 2003 Sep;4(9):712-20
references: 14506474
references: Mol Cell Biol. 2008 Feb;28(4):1373-82
references: 18086882
references: Carcinogenesis. 2007 Sep;28(9):1906-13
references: 17389609
references: Nat Rev Mol Cell Biol. 2010 Mar;11(3):196-207
references: 20177395
references: Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1368-73
references: 18559551
references: Cell Res. 2008 Jan;18(1):114-24
references: 18166980
references: Neurotherapeutics. 2009 Jul;6(3):427-35
references: 19560733
references: Oncogene. 2006 Sep 25;25(43):5864-74
references: 16998501
references: J Biol Chem. 1999 Sep 3;274(36):25571-5
references: 10464290
references: J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86
references: 12615961
references: EMBO J. 2008 May 7;27(9):1368-77
references: 18388863
references: EMBO J. 2011 Mar 16;30(6):1079-92
references: 21317870
references: Mol Cell Biol. 2004 Jan;24(2):708-18
references: 14701743
references: PLoS One. 2009 Oct 13;4(10):e7443
references: 19823589
references: Mol Cancer Res. 2009 Jul;7(7):989-99
references: 19609002
references: J Clin Invest. 2009 May;119(5):1124-35
references: 19425167
references: CA Cancer J Clin. 2010 May-Jun;60(3):166-93
references: 20445000
references: Neuro Oncol. 2011 May;13(5):459-70
references: 21398658
references: Bioessays. 2004 Aug;26(8):882-93
references: 15273990
references: Nature. 2005 Apr 14;434(7035):917-21
references: 15829967
references: N Engl J Med. 2009 Jul 9;361(2):123-34
references: 19553641
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: DNA Repair (Amst). 2004 Aug-Sep;3(8-9):909-18
references: 15279776
references: Cancer Res. 2006 Dec 1;66(23):11179-86
references: 17145862
references: Curr Oncol Rep. 2011 Dec;13(6):442-9
references: 21913063
references: J Neurooncol. 2008 Jun;88(2):135-42
references: 18330515
references: DNA Repair (Amst). 2005 Jun 8;4(6):649-54
references: 15907772
references: Cytogenet Genome Res. 2004;104(1-4):14-20
references: 15162010
references: Cell. 2002 Mar 22;108(6):781-94
references: 11955432
references: Mol Cell. 2006 May 19;22(4):511-9
references: 16713581
references: Ann Oncol. 2011 Feb;22(2):268-79
references: 20643861
references: Biochim Biophys Acta. 2010 May;1804(5):1136-50
references: 19631767
references: EMBO J. 2003 Oct 15;22(20):5612-21
references: 14532133
references: Hum Mutat. 2008 Mar;29(3):381-9
references: 18165945
references: Nature. 1997 Jul 31;388(6641):495-8
references: 9242411
references: Genome Res. 2011 Apr;21(4):505-14
references: 21393386
references: Cell Cycle. 2003 Jul-Aug;2(4):339-45
references: 12851486
references: Neuro Oncol. 2002 Jul;4(3):196-211
references: 12084351
references: Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S20-7
references: 20171513
references: J Clin Neurosci. 2010 Apr;17(4):417-21
references: 20167494